GHP NewsLatest Science Needle-free pan-sarbecovirus vaccine clears phase 1 safety milestone, but broad protection remains unproven Summary This open-label, first-in-human phase 1 dose-escalation trial evaluated the DNA vaccine pEVAC-PS, a computationally designed pan-sarbecovirus candidate delivered intradermally by needle-free PharmaJet Tropis in... 21 July, 20262 min read